Pathologic patterns of interleukin 10 expression - A review

Biochemia Medica

Volumn 25, Issue 1, 2015, Pages 36-48

  Trifunović, Jasenka ^a   Miller, Larisa ^b   Debeljak, Željko ^c   Horvat, Vesna ^c  

^a Department of Medical Biochemistry Special Hospital for Medical Rehabilitation Vara dinske Toplice   (Croatia)

^b EMD Serono Research and Development Institute   (United States)

^c UNIVERSITY HOSPITAL OSIJEK   (Croatia)

Author keywords

Autoimmune diseases; Genetic; Inflammatory diseases; Interleukin 10; Neoplasms; Polymorphisms

Indexed keywords

INTERLEUKIN 10; IL10 PROTEIN, MOUSE;

ALLELE; ASTHMA; B LYMPHOCYTE; CHROMOSOME 1Q; CYTOKINE PRODUCTION; DOWN REGULATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; INFLAMMATORY BOWEL DISEASE; MELANOMA; MONOCYTE; PATHOPHYSIOLOGY; PROMOTER REGION; PROTEIN EXPRESSION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS; UPREGULATION; ANIMAL; BIOSYNTHESIS; DINUCLEOTIDE REPEAT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFLAMMATION; METABOLISM; PATHOLOGY;

ANIMALS; DINUCLEOTIDE REPEATS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERLEUKIN-10; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84922571115     PISSN: 13300962     EISSN: None     Source Type: Journal    
DOI: 10.11613/BM.2015.004     Document Type: Review

References (77)

1. Gastl GA, Abrams JS, Nanus DM, Oosterkamp R, Silver J, Liu F, et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 1993;55:96-101. http://dx.doi.org/10.1002/ ijc.2910550118
2. Pisa P, Halapi E, Pisa EK, Gerdin E, Hising C, Bucht A, et al. Selective expression of interleukin 10, interferon-gamma and granulocyte-macrophage colony-stimulating factor in ovarian cancer biosies. Proc Nat Acad Sci USA 1992;89:7708-12. http://dx.doi.org/10.1073/pnas.89.16.7708
3. Spits H, De Waal Malefyt R. Functional characterization of human IL-10. Int Arch Allergy Appl Immunol 1992;99:8-15. http://dx.doi.org/10.1159/000236329
4. Eskdale J, Gallagher G. A polymorphic dinucleotide repeat in the human IL-10 promoter. Immunogenetics 1995:42:444-5. http://dx.doi.org/10.1007/BF00179416
5. Eskdale J, Kube D, Gallagher G. A second polymorphic dinucleotide repeat in the 5 flanking region of the human IL10 gene. Immunogenetics 1996;45:82-3. http://dx.doi. org/10.1007/s002510050174
6. Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the human IL10 gene and further characterization of the 5 flanking sequence. Immunogenetics 1997;46:120-8. http:// dx.doi.org/10.1007/s002510050250
7. Defrance T, Vanbervliet B, Briere F, Durand I, Rousset F, Banchereau J. Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med 1992;175:671-82. http://dx.doi.org/10.1084/jem.175.3.671
8. Borish L, Aarons A, Rumbyrt J, Cvietusa P, Negri J, Wenzel S. Interleukin-10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol 1996;97:1288-96. http://dx.doi.org/10.1016/S0091-6749(96)70197-5
9. Rosenwasser LJ, Borish L. Genetics of Atopy and Asthma: The Rationale behind Promoter-based Candidate Gene Studies (IL-4 and IL-10). Am J Respir Crit Care Med 1997;156:152-5. http://dx.doi.org/10.1164/ ajrccm.156.4.12tac-14
10. Chatterjee R, Batra J, Kumar A, Mabalirajan U, Nahid S, Niphadkar PV, Ghosh B. Interleukin 10 promoter polymorphisms and atopic asthma in North Indians. Clin Exp Allergy 2005;35:914-9. http://dx.doi.org/10.1111/j.1365-2222.2005.02273.x
11. Zheng XY, Guan WJ, Mao C, Chen HF, Ding H, Zheng JP, et al. Interleukin-10 promoter 1082/-819/-592 polymorphisms are associated with asthma susceptibility in Asians and atopic asthma: a meta-analysis. Lung 2014;192:65-73. http://dx.doi.org/10.1007/s00408-013-9519-8
12. Nie W, Fang Z, Li B, Xiu QY. Interleukin-10 promoter polymorphisms and asthma risk: a meta-analysis. Cytokine 2012;60:849-55. http://dx.doi.org/10.1016/j. cyto.2012.08.023
13. Hyun MH, Lee CH, Kang MH, Park BK, Lee YH. Interleukin-10 Promoter Gene Polymorphisms and Susceptibility to Asthma: A Meta-Analysis. PLoS ONE 2013;8:e53758. http:// dx.doi.org/10.1371/journal.pone.0053758
14. Peng H, Wang W, Zhou M, Li R, Pan HF, Ye DQ. Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus. Clin Rheumatol 2013;32:1255-66. http:// dx.doi.org/10.1007/s10067-013-2294-3
15. Llorente L, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Maillot MC, Durand-Gasselin I, et al. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw 1993;4:421-7
16. Rahman A. Meeting report: Cytokines in systemic lupus erythematosus, London, UK. Arthritis Res Ther 2003;5:160-4. http://dx.doi.org/10.1186/ar767
17. Llorente L, Zou W, Levy Y. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995;181:839-44. http://dx.doi.org/10.1084/ jem.181.3.839
18. Arora V, Verma J, Marwah V, Kumar A, Anand D, Das N. Cytokine imbalance in systemic lupus erythematosus: a study on northern Indian subjects. Lupus 2012;21:596-603. http://dx.doi.org/10.1177/0961203311434937
19. Schotte H, Willeke P, Becker H, Poggemeyer J, Gaubitz M, Schmidt H, Schluter B. Association of extended interleukin-10 promoter haplotypes with disease susceptibility and manifestations in German patients with systemic lupus erythematosus. Lupus 2014;23:378-85. http://dx.doi. org/10.1177/0961203314522334
20. da Silva HD, da Silva AP, da Silva HA, Asano NM, Maia Mde M, de Souza PR. Interferon gamma and Interleukin 10 polymorphisms in Brazilian patients with systemic lupus erythematosus. Mol Biol Rep 2014;41:2493-500. http:// dx.doi.org/10.1007/s11033-014-3106-9
21. Sharif MN, Tassiulas I, Hu Y, Mecklenbrauker I, Tarakhovsky A, Ivashkiv LB. IFN-alpha Priming Results in a Gain of Proinflammatory Function by IL-10: Implications for Systemic Lupus Erythematosus Pathogenesis. J Immunol 2004;172:6476-81. http://dx.doi.org/10.4049/jimmunol. 172.10.6476
22. Ronnelid J, Tejde A, Mathsson L, Nilsson-Ekdahl K, Nilsson B. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann Rheum Dis 2003;62:37-42. http://dx.doi.org/10.1136/ ard.62.1.37
23. Wang B, Fan YG, Ye DQ. Lack of association between the haplotype GCC/ATA polymorphism in the IL-10 promoter and SLE risk: evidence from a meta-analysis. Z Rheumatol 2013;72:705-8. http://dx.doi.org/10.1007/s00393-013-1158-1
24. Liu P, Song J, Su H, Li L, Lu N, Yang R, Peng Z. IL-10 Gene Polymorphisms and Susceptibility to Systemic Lupus Erythematosus: A Meta-Analysis. PloS ONE 2013;8:e69547. http://dx.doi.org/10.1371/journal.pone.0069547
25. Song GG, Choi SJ, Ji JD, Lee YH. Associations between interleukin-10 polymorphisms and susceptibility to systemic lupus erythematosus: a meta-analysis. Hum Immunol 2013;74:364-70. http://dx.doi.org/10.1016/j.humimm. 2012.11.020
26. Zhou M, Ding L, Peng H, Wang B, Huang F, Xu WD, et al. Association of the interleukin-10 gene polymorphism (-1082A/G) with systemic lupus erythematosus: a meta-analysis. Lupus 2013;22:128-35. http://dx.doi. org/10.1177/0961203312468623
27. Nath SK, Harley JB, Lee YH. Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: a meta-analysis. Hum Genet 2005;118:225-34. http://dx.doi.org/10.1007/s00439-005-0044-6
28. Asadullah K, Sabat R, Friedrich M, Volk HD, Sterry W. Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:185-92. http://dx.doi. org/10.2174/1568010043343886
29. Karam RA, Zidan HE, Khater MH. Polymorphisms in the TNF-α and IL-10 gene promoters and risk of psoriasis and correlation with disease severity. Cytokine 2014;66:101-5. http://dx.doi.org/10.1016/j.cyto.2014.01.008
30. Kingo K, Koks S, Silm H, Vasar E. IL-10 promoter polymorphisms influence disease severity and course in psoriasis. Genes Immun 2003;4:455-7. http://dx.doi.org/10.1038/ sj.gene.6364004
31. Lee YH, Choi SJ, Ji JD, Song GG. Associations between interleukin-10 polymorphisms and susceptibility to psoriasis: a meta-analysis. Inflamm Res 2012;61:657-63. http://dx.doi. org/10.1007/s00011-012-0458-2
32. Fernandez L, Martinez A, Mendoza JL, Urcelay E, Fernandez-Arquero M, Garcia-Paredes J, et al. Interleukin-10 polymorphisms in IBD Spanish patients. Inflamm Bowel Dis 2005;11:739-43. http://dx.doi.org/10.1097/01. MIB.0000173457.64868.20
33. Zhu H, Lei X, Liu Q, Wang Y. Interleukin-10-1082A/G polymorphism and inflammatory bowel disease susceptibility: A meta-analysis based on 17,585 subjects. Cytokine 2013;61:146-53. http://dx.doi.org/10.1016/j.cyto 2012. 09.009
34. Lv H, Jiang Y, Li J, Zhang M, Shang Z, Zheng J, et al. Association between polymorphisms in the promoter region of interleukin-10 and susceptibility to inflammatory bowel disease. Mol Biol Rep 2014;41:1299-310. http://dx.doi. org/10.1007/s11033-013-2975-7
35. Isomaki P, Luukkainen R, Saario R, Toivanen P, Punnonen J. Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Arthritis Rheum 1996;39:386-95. http://dx.doi.org/10.1002/art.1780390306
36. MacDonald KP, Pettit AR, Quinn C, Thomas GJ, Thomas R. Resistance of rheumatoid synovial dendritic cells to the immunosuppressive effects of IL-10. J Immunol 1999;163:5599-607
37. Antoniv TT, Ivashkiv LN. Dysregulation of Interleukin-10- Dependent Gene Expression in Rheumatoid Arthritis Synovial Macrophages. Arthritis Rheum 2006;54:2711-21. http://dx.doi.org/10.1002/art.22055
38. Lapadula G, Iannone F, Dell’Accio F, Covelli M, Pipitone V. Interleukin-10 in rheumatoid arthritis. Clin Exp Rheumatol 1995;13:629-32
39. Avramescu C, Vere CC, Margaritescu CL, Turculeanu A, Balasoiu M, Rogoz S. Cytokinic panel in rheumatoid arthritis and correlation with histological patterns of synovitis - active type of disease. Rom J Morphol Embryo 2005;46:87-92
40. Lacki JK, Klama K, Porawska W, Mackiewicz SH, Muller W, Wiktorowicz K. Interleukin 10 inhibits interleukin 6 production and acute phase response in rheumatoid arthritis. Arch Immunol Ther Exp 1995;43:11-4
41. St Clair EW. Interleukin 10 treatment for rheumatoid arthritis. Ann Rheum Dis 1999;58:99-102. http://dx.doi. org/10.1136/ard.58.2008.i99
42. de Paz B, Alperi-Lopez M, Ballina-Garcia FJ, Prado C, Mozo L, Gutierrez C, Suarez A. Interleukin 10 and tumor necrosis factor-alpha genotypes in rheumatoid arthritis-association with clinical response to glucocorticoids. J Rheumatol 2010;37:503-11. http://dx.doi.org/10.3899/jrheum.090566
43. Paradowska-Gorycka A, Trefler J, Maciejewska-Stelmach J, Lacki JK. Interleukin-10 gene promoter polymorphism in Polish rheumatoid arthritis patients. Int J Immunogenet 2010;37:225-31. http://dx.doi.org/10.1111/j.1744-313X.2010.00913.x
44. Zhang J, Zhang Y, Jin J, Li M, Xie K, Wen C, et al. The-1082A/G polymorphism in the Interleukin-10 gene and the risk of rheumatoid arthritis: a meta-analysis. Cytokine 2011;56:351-5. http://dx.doi.org/10.1016/j. cyto.2011.05.022
45. Lee YH, Bae SC, Choi SJ, Ji JD, Song GG. Associations between interleukin-10 polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis. Mol Biol Rep 2012;39:81-7. http://dx.doi.org/10.1007/s11033-011-0712-7
46. Ying B, Shi Y, Pan X, Song X, Huang Z, Niu Q, et al. Association of polymorphisms in the human IL-10 and IL-18 genes with rheumatoid arthritis. Mol Biol Rep 2011;38:379-85. http://dx.doi.org/10.1007/s11033-010-0119-x
47. Turner J, Gonzalez-Juarrero M, Ellis DL, Basaraba RJ, Kipnis A, Orme IM, Cooper AM. In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J Immunol 2002;169:6343-51. http://dx.doi.org/10.4049/ jimmunol.169.11.6343
48. Wang JY, Chang HC, Liu JL, Shu CC, Lee CH, Wang JT, Lee LN. Expression of toll-like receptor 2 and plasma level of interleukin-10 are associated with outcome in tuberculosis. Eur J Clin Microbiol Infect Dis 2012;31:2327-33. http://dx.doi. org/10.1007/s10096-012-1572-3
49. Redford PS, Murray PJ, O’Garra A. The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol 2011;4:261-70. http://dx.doi.org/10.1038/ mi.2011.7
50. O’Leary S, O’Sullivan MP, Keane J. IL-10 blocks phagosome maturation in mycobacterium tuberculosis-infected human macrophages. Am J Respir Cell Mol Biol 2011;45:172-80. http://dx.doi.org/10.1165/rcmb.2010-0319OC
51. Verbon A, Juffermans N, Van Deventer SJ, Speelman P, Van Deutekom H, Van Der Poll T. Serum concentrations of cytokines in patients with active tuberculosis (TB) and after treatment. Clin Exp Immunol 1999:115:110-3. http://dx.doi. org/10.1046/j.1365-2249.1999.00783.x
52. Barnes PF, Lu S, Abrams JS, Wang E, Yamamura M, Modlin RL. Cytokine production at the site of disease in human tuberculosis. Infect Immun 1993;61:3482-9
53. Mosaad YM, Soliman OE, Tawhid ZE, Sherif DM. Interferon-gamma +874 T/A and Interleukin-10-1082 A/G Single nucleotide Polymorphism in Egyptian Children with Tuberculosis. Scand J Immunol 2010;72:358-64. http://dx.doi. org/10.1111/j.1365-3083.2010.02426.x
54. Zhang J, Chen Y, Nie XB, Wu WH, Zhang H, Zhang M, et al. Interleukin-10 polymorphisms and tuberculosis susceptibility: a meta-analysis. Int J Tuberc Lung Dis 2011;15:594-601. http://dx.doi.org/10.5588/ijtld.09.0703
55. Ansari A, Talat N, Jamil B, Hasan Z, Razzaki T, Dawood G, Hussain R. Cytokine Gene Polymorphisms across Tuberculosis Clinical Spectrum in Pakistani Patients. PLoS ONE 2009;4:e4778. http://dx.doi.org/10.1371/journal. pone.0004778
56. Meenakshi P, Ramya S, Shruthi T, Lavanya J, Mohammed HH, Mohammed SA, et al. Association of IL-1β +3954 C/T and IL-10-1082 G/A cytokine gene polymorphisms with susceptibility to tuberculosis. Scand J Immunol 2013;78:92-7. http://dx.doi.org/10.1111/sji.12055
57. Liang B, Guo Y, Li Y, Kong H. Association between IL-10 gene polymorphisms and susceptibility of tuberculosis: evidence based on a meta-analysis. PLoS One 2014;9:e88448. http:// dx.doi.org/10.1371/journal.pone.0088448
58. Kriiger-Krasagakes S, Krasagakis K, Garbe C, Schmitt E, Hiuls C, Blankensteinl T, Diamantstein T. Expression of interleukin 10 in human melanoma. Br J Cancer 1994;70:1182-5. http://dx.doi.org/10.1038/bjc.1994.469
59. Sato T, McCue P, Masuoka K, Salwen S, Lattime EC, Mastrangelo MJ, Berd D. Interleukin 10 production by human melanoma. Clin Cancer Res 1996;2:1383-90
60. Eijun I, Rong-Rong H, Duan-Ren W, Eberhard P, Wunsch PH, Cochran AJ. IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod Pathol 2011;24:801-9. http://dx.doi.org/10.1038/ modpathol.2011.5
61. Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S, Burg G. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997;71:630-7. http://dx.doi.org/10.1002/(SICI)1097-0215(19970516)71:4<630::AID-IJC20>3.0.CO;2-E
62. Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO. Metastatic Melanoma Secreted IL-10 Down-Regulates CD1 Molecules on Dendritic Cells in Metastatic Tumor Lesions. Am J Pathol 2004;165:1853-63. http://dx.doi.org/10.1016/ S0002-9440(10)63238-5
63. Howell WM, Turner SJ, Bateman AC, Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2001;2:25-31. http://dx.doi.org/10.1038/sj.gene.6363726
64. Vuoristo MS. The polymorphisms of interleukin-10 gene influence the prognosis of patients with advanced melanoma. Cancer Genet Cytogen 2007;176:54-7. http://dx.doi. org/10.1016/j.cancergencyto.2007.03.002
65. Shih CM, Lee YL, Chiou HL, Hsu WF, Chen WE, Chou MC, Lin LY. The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. Lung Cancer 2005;50:291-7. http://dx.doi.org/10.1016/j. lungcan.2005.07.007
66. Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, Rigal D, et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large Bcell lymphoma. Blood 2004;103:3529-34. http://dx.doi. org/10.1182/blood-2003-06-1850
67. Cao HY, Zou P, Zhou H. Genetic association of interleukin-10 promoter polymorphisms and susceptibility to diffuse large B-cell lymphoma: a meta-analysis. Gene 2013;519:288-94. http://dx.doi.org/10.1016/j.gene.2013.01.066
68. Matsumoto K, Oki A, Satoh T, Okada S, Minaguchi T, Onuki M, et al. Interleukin-10-1082 gene polymorphism and susceptibility to cervical cancer among Japanese women. Jpn J Clin Oncol 2010;40:1113-6. http://dx.doi.org/10.1093/ jjco/hyq094
69. Vairaktaris E, Yapijakis C, Serefoglou Z, Derka S, Vassiliou S, Nkenke E, et al. The interleukin-10 (-1082A/G) polymorphism is strongly associated with increased risk for oral squamous cell carcinoma. Anticancer Res 2008;28:309-14
70. Yu Z, Liu Q, Huang C, Wu M, Li G. The interleukin 10-819C/ T polymorphism and cancer risk: a HuGE review and meta-analysis of 73 studies including 15,942 cases and 22,336 controls. OMICS 2013;17:200-14. http://dx.doi. org/10.1089/omi.2012.0089
71. Faupel-Badger JM, Kidd LC, Albanes D, Virtamo J, Woodson K, Tangrea JA. Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control 2008;19:119-24. http://dx.doi.org/10.1007/s10552-007-9077-6
72. Cacev T, Radosevic S, Krizanac S, Kapitanovic S. Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis 2008;29:1572-80. http://dx.doi.org/10.1093/carcin/bgn164
73. Liu J, Song B, Bai X, Liu W, Li Z, Wang J, et al. Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese. BMC Cancer 2010;10:456-62. http://dx.doi.org/10.1186/1471-2407-10-456
74. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy--review of a new approach. Pharmacol Rev 2003;55:241-69. http://dx.doi.org/10.1124/pr.55.2.4
75. Li MC, He SH. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol 2004;10:620-5
76. Walsh GM. Novel therapies for asthma-advances and problems. Curr Pharm Des 2005;11:3027-38. http://dx.doi. org/10.2174/1381612054864984
77. Clark DN, Markham JL, Sloan CS, Poole BD. Cytokine inhibition as a strategy for treating systemic lupus erythematosus. Clin Immunol 2013;148:335-43. http://dx.doi. org/10.1016/j.clim.2012.11.001.